

# Vasilis Stavrinides,, Mrcs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7186874/publications.pdf>

Version: 2024-02-01

37  
papers

529  
citations

687220

13  
h-index

677027

22  
g-index

37  
all docs

37  
docs citations

37  
times ranked

799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?. British Journal of Radiology, 2022, 95, 20210321.	1.0	5
2	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.2	13
3	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	1.2	2
4	Magnetic Resonance Imaging-guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies. European Urology Open Science, 2022, 38, 40-43.	0.2	5
5	Image quality assessment for machine learning tasks using meta-reinforcement learning. Medical Image Analysis, 2022, 78, 102427.	7.0	19
6	Orchidopexy for Testicular Torsion: A Systematic Review of Surgical Technique. European Urology Focus, 2021, 7, 1493-1503.	1.6	22
7	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	1.3	15
8	Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. European Radiology, 2021, 31, 1644-1655.	2.3	37
9	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. European Urology, 2021, 79, 20-29.	0.9	13
10	Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and Quality. Urology, 2021, 148, 316-317.	0.5	1
11	Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still out. BJU International, 2021, 127, 169-170.	1.3	5
12	Adaptable Image Quality Assessment Using Meta-Reinforcement Learning of Task Amenability. Lecture Notes in Computer Science, 2021, , 191-201.	1.0	4
13	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. Cancers, 2021, 13, 1985.	1.7	10
14	Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. Letter.. Journal of Urology, 2021, 205, 1233-1234.	0.2	0
15	Morphological Change Forecasting For Prostate Glands Using Feature-Based Registration And Kernel Density Extrapolation. , 2021, , .		1
16	Followup of Men with PI-RADS TM 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.. Journal of Urology, 2021, 205, 1526-1528.	0.2	0
17	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. Prostate Cancer and Prostatic Diseases, 2021, 24, 1028-1031.	2.0	10
18	Cellular senescence as a possible link between prostate diseases of the ageing male. Nature Reviews Urology, 2021, 18, 597-610.	1.9	19

#	ARTICLE	IF	CITATIONS
19	Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study. <i>European Radiology</i> , 2020, 30, 2082-2090.	2.3	20
20	Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carroll's Letter to the Editor re: Vasilis Stavrinos, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443-451. <i>European Urology</i> , 2020, 78, e112-e113.	0.9	0
21	Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Vasilis Stavrinos, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443-451. <i>European Urology</i> , 2020, 78, e166.	0.9	0
22	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. <i>Scientific Reports</i> , 2020, 10, 17177.	1.6	4
23	Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISE. <i>British Journal of Radiology</i> , 2020, 93, 20200819.	1.0	11
24	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. <i>European Urology</i> , 2020, 78, 163-170.	0.9	60
25	Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>European Urology</i> , 2020, 78, 443-451.	0.9	94
26	Mycobacterial immunotherapy for prostate cancer: where can we go from here?. <i>Nature Reviews Urology</i> , 2020, 17, 189-190.	1.9	2
27	Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020, 204, 1065-1066.	0.2	0
28	MRI in active surveillance: a critical review. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 5-15.	2.0	36
29	The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing. <i>Cancers</i> , 2019, 11, 1233.	1.7	31
30	Stroma in normal and cancer wound healing. <i>FEBS Journal</i> , 2019, 286, 2909-2920.	2.2	27
31	Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates. <i>Prostate</i> , 2018, 78, 1229-1237.	1.2	9
32	Can MRI Replace Biopsy in Men on Surveillance?. <i>Current Clinical Urology</i> , 2018, , 111-119.	0.0	0
33	When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers. <i>Cancer Treatment Reviews</i> , 2017, 58, 14-21.	3.4	12
34	Isolated bilateral simplex ureteric ectopia: Bladder capacity as an indicator of continence outcome. <i>Journal of Pediatric Urology</i> , 2017, 13, 493.e1-493.e9.	0.6	2
35	MP51-12 A TRAINING COURSE FOR THE UROLOGIST IMPROVES THEIR ABILITY TO INTERPRET CLINICALLY SIGNIFICANT PROSTATE CANCER ON MULTIPARAMETRIC MRI. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
36	A Case of Persistent Foot Pain in a Neurofibromatosis Type I Patient. <i>Case Reports in Medicine</i> , 2012, 2012, 1-3.	0.3	2

#	ARTICLE	IF	CITATIONS
37	Outcome in surgically treated Rathke's cleft cysts: long-term monitoring needed. European Journal of Endocrinology, 2011, 165, 33-37.	1.9	38